The impact of next generation sequencing studies on the diagnosis of BAP1 inactivated melanocytic tumors.
Next generation sequencing results were associated with higher diagnostic accuracy among dermatopathologists assessing BAP1 inactivated melanocytic tumors.
The impact of next generation sequencing studies on the diagnosis of BAP1 inactivated melanocytic tumors.
Next generation sequencing (next generation sequencing) is becoming increasingly utilized in melanocytic pathology.
We conducted a two-phase survey with 26 dermatopathologists from the International Melanoma Pathology Study Group to assess the impact of next generation sequencing on diagnostic accuracy and interobserver agreement in 31 BIMTs.
seeing next generation sequencing results made dermatopathologists more likely to reach the correct diagnosis
BAP1 inactivated melanocytic tumors (BIMTs) are recognized for their potential for significant morphologic atypia including nuclear atypia, expansile growth, and mitotic activity, making it difficult to form firm morphologic criteria for malignancy.
After next generation sequencing results, interobserver agreement improved from fair on Survey 1 (κ = 0.348) to moderate on Survey 2 (κ = 0.441).
When accounting for case variability and difficulty, respondents were 8.7 times more likely to provide a correct diagnosis for a given case (CMH OR = 8.69, 95% CI [4.89-15.44], p < 0.001).
Additional studies with greater case numbers and follow-up are needed to further validate these findings.